Answers are grounded in this paper and cite their sources.
There is a lack of real-world evidence regarding the impact of concomitant metformin and renin-angiotensin system inhibitors (RASis) on sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated kidney outcomes. This study was aimed to investigate whether SGLT2i-associated kidney outcomes were modified by the concomitant use of metformin or RASis in patients with type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Chong et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: